Drug Profile
Research programme: radiolabeled ACE diagnostics - Molecular Insight Pharmaceuticals
Alternative Names: MIP-190Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure(Diagnosis) in USA
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
- 25 Mar 2008 Preclinical development is ongoing